KALV Stock Price, KalVista Pharmaceuticals Quote, Chart

Market Summary

USD11.32+0.31

Delayedas of 30 Apr 2024, 01:06 pm

2.82%

KALV Stock Price

View Fullscreen

KALV RSI Chart

KALV Valuation

Market Cap

464.5M

Price/Earnings (Trailing)

-4.29

Price/Sales (Trailing)

43.65

EV/EBITDA

-5.8

Price/Free Cashflow

-4.8

KALV Price/Sales (Trailing)

KALV Profitability

EBT Margin

-732.13%

Return on Equity

-122.26%

Return on Assets

-95.03%

Free Cashflow Yield

-20.85%

KALV Fundamentals

KALV Revenue

Revenue (TTM)

12.7M

KALV Earnings

Earnings (TTM)

-108.3M

Earnings Growth (Yr)

-36.26%

Earnings Growth (Qtr)

-4.98%

Breaking Down KALV Revenue

52 Week Range

8.7511.45

(Low)(High)

Last 7 days

-3.8%

Last 30 days

-7.2%

Last 90 days

-25.7%

Trailing 12 Months

29.1%

How does KALV drawdown profile look like?

KALV Financial Health

Current Ratio

5.44

KALV Investor Care

Shares Dilution (1Y)

23.47%

Diluted EPS (TTM)

-3.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	11.8M	12.7M	0	0
2019	18.0M	16.1M	15.8M	14.1M
2018	3.7M	8.4M	12.0M	16.5M
2017	1.6M	1.5M	655.0K	1.6M
2016	0	2.1M	1.9M	1.7M
2015	916.5K	1.8M	0	0
2014	318.5K	222.0K	125.5K	29.0K
2013	0	0	0	415.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of KalVista Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	yea christopher	sold	-170,124	14.1147	-12,053	chief development officer
Feb 20, 2024	audhya paul k.	sold	-201,774	14.115	-14,295	chief medical officer
Feb 20, 2024	palleiko benjamin l	sold	-321,846	14.1148	-22,802	cfo, cbo
Feb 20, 2024	crockett thomas andrew	sold	-351,289	14.1148	-24,888	ceo
Feb 20, 2024	feener edward p.	sold	-397,929	14.0671	-28,288	chief scientific officer
Feb 17, 2024	yea christopher	acquired	-	-	18,788	chief development officer
Feb 17, 2024	palleiko benjamin l	acquired	-	-	51,029	cfo, cbo
Feb 17, 2024	crockett thomas andrew	acquired	-	-	54,415	ceo
Feb 17, 2024	feener edward p.	acquired	-	-	18,788	chief scientific officer
Feb 17, 2024	audhya paul k.	acquired	-	-	30,613	chief medical officer

Which funds bought or sold KALV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	added	11.28	95,459	1,328,950	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	40,000	40,000	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	new	-	17,790	17,790	-%
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-4.00	-259,498	3,415,500	3.19%
Apr 24, 2024	AlphaCentric Advisors LLC	reduced	-5.11	-136,450	1,541,800	0.93%
Apr 23, 2024	AMALGAMATED BANK	reduced	-49.12	-13,000	13,000	-%
Apr 22, 2024	Vivo Capital, LLC	sold off	-100	-10,486,100	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	34.26	85,179	205,506	-%
Apr 19, 2024	Red Tortoise LLC	unchanged	-	-73.00	2,218	-%
Apr 15, 2024	Legato Capital Management LLC	new	-	280,774	280,774	0.03%

Are Funds Buying or Selling KALV?

Are funds buying KALV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KALV

No. of Funds

Unveiling KalVista Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	tcg crossover gp i, llc	3.2%	1,345,826	SC 13D/A
Feb 26, 2024	adage capital partners gp, l.l.c.	6.87%	2,845,000	SC 13G
Feb 22, 2024	frazier life sciences public fund, l.p.	3.6%	1,504,956	SC 13D/A
Feb 20, 2024	tcg crossover gp i, llc	6.52%	2,700,840	SC 13D/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	14.0%	4,824,731	SC 13G/A
Feb 14, 2024	tang capital partners lp	9.96%	3,440,345	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	7.8%	2,684,005	SC 13G/A
Feb 13, 2024	vanguard group inc	5.15%	1,781,419	SC 13G
Feb 12, 2024	saturn v capital management lp	4.1%	1,431,259	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A

Recent SEC filings of KalVista Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	3	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 22, 2024	8-K	Current Report
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Mar 11, 2024	10-Q	Quarterly Report
Mar 11, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report
Feb 26, 2024	SC 13G	Major Ownership Report
Feb 22, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to KalVista Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

KalVista Pharmaceuticals Inc News

Latest updates

KalVista Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q3	2016Q2	2016Q2	2016Q1	2016Q1
Revenue	142.5%	4.00	2.00	4.00	3.00	3.00	4.00	6.00	4.00	5.00	2.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00
Operating Expenses	-10.6%	13.00	14.00	13.00	13.00	14.00	11.00	10.00	11.00	8.00	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	7.4%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-15.6%	9.00	11.00	10.00	10.00	11.00	8.00	8.00	8.00	6.00	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-500*	-	0.00	-	0.00	-
Net Income	29.1%	-6.58	-9.29	-5.90	-7.34	-8.53	-3.96	-3.30	-5.03	-0.66	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.9%	114	139	160	183	203	163	182	204	225	244	259	272	66.00	75.00	84.00	93.00	103	112	120	118	127
Current Assets	-19.1%	104	129	150	172	192	151	170	194	214	234	250	264	63.00	72.00	80.00	89.00	99.00	108	116	116	124
Cash Equivalents	-60.0%	23.00	58.00	49.00	56.00	85.00	39.00	38.00	31.00	46.00	46.00	48.00	51.00	18.00	16.00	18.00	16.00	19.00	22.00	30.00	32.00	56.00
Net PPE	-3.2%	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Current Liabilities	7.8%	19.00	18.00	14.00	15.00	12.00	11.00	10.00	12.00	10.00	10.00	8.00	10.00	7.00	10.00	8.00	8.00	10.00	10.00	14.00	18.00	19.00
Shareholder's Equity	-22.6%	89.00	114	139	161	184	144	165	185	208	227	244	257	59.00	65.00	74.00	84.00	90.00	98.00	102	97.00	104
Retained Earnings	-7.3%	-425	-396	-368	-343	-316	-295	-273	-250	-226	-203	-183	-167	-152	-142	-132	-121	-115	-115	-99.81	-92.48	-83.95
Additional Paid-In Capital	0.6%	517	514	511	507	505	445	442	439	436	433	430	426	213	210	208	207	206	205	204	191	190
Shares Outstanding	0.5%	35.00	34.00	34.00	34.00	28.00	25.00	25.00	25.00	24.00	24.00	24.00	19.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	120	-	-	-	379	-	-	-	282	-	-	-	164	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-39.1%	-27,571	-19,825	-26,730	-22,636	-9,289	-20,594	-22,742	-26,789	-14,065	-19,545	-17,735	-11,045	-7,586	-7,952	-3,588	-12,618	-13,109	-7,814	-11,275	-10,511	-10,856
Share Based Compensation	-15.5%	2,711	3,207	3,254	2,441	2,333	2,506	2,642	2,654	2,777	2,860	2,795	3,441	1,241	1,248	1,188	1,090	1,122	1,162	1,074	846	797
Cashflow From Investing	-123.5%	-6,702	28,556	19,613	-6,210	-2,517	20,098	30,044	12,434	12,902	17,643	14,881	-166,483	6,945	6,371	5,513	10,027	9,770	-1,514	-1,530	-14,047	-54,589
Cashflow From Financing	121.9%	284	128	204	-33.00	57,813	168	168	138	772	63.00	608	210,308	1,703	60.00	46.00	1.00	45.00	138	11,400	155	56.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KALV Income Statement

2024-01-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Operating expenses:
Research and development	$ 22,523	$ 20,063	$ 60,919	$ 56,325
General and administrative	10,628	6,882	31,071	22,818
Total operating expenses	33,151	26,945	91,990	79,143
Operating loss	(33,151)	(26,945)	(91,990)	(79,143)
Other income:
Interest income	684	732	2,383	1,424
Foreign currency exchange gain (loss)	1,120	597	277	(237)
Other income	2,319	4,313	7,335	11,354
Total other income	4,123	5,642	9,995	12,541
Net loss	(29,028)	(21,303)	(81,995)	(66,602)
Other comprehensive (loss) income:
Foreign currency translation (loss) gain	(46)	1,128	(373)	(573)
Unrealized holding gain on marketable securities	438	658	1,270	808
Reclassification adjustment for realized (gain) loss on marketable securities included in net loss	(221)	(1)	(1,130)	84
Other comprehensive gain (loss)	171	1,785	(233)	319
Comprehensive loss	$ (28,857)	$ (19,518)	$ (82,228)	$ (66,283)
Net loss per share to common stockholders, basic	$ (0.84)	$ (0.75)	$ (2.37)	$ (2.58)
Net loss per share to common stockholders, diluted	$ (0.84)	$ (0.75)	$ (2.37)	$ (2.58)
Weighted average common shares outstanding, basic	34,723,379	28,278,453	34,567,853	25,810,369
Weighted average common shares outstanding, diluted	34,723,379	28,278,453	34,567,853	25,810,369

KALV Balance Sheet

2024-01-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2024	Apr. 30, 2023
Current assets:
Cash and cash equivalents	$ 23,056	$ 56,238
Marketable securities	52,530	93,137
Research and development tax credit receivable	23,011	16,568
Prepaid expenses and other current assets	5,506	6,383
Total current assets	104,103	172,326
Property and equipment, net	2,423	2,948
Right of use assets	7,045	7,822
Other assets	397	106
Total assets	113,968	183,202
Current liabilities:
Accounts payable	3,101	4,817
Accrued expenses	14,840	9,128
Lease liability - current portion	1,187	1,087
Total current liabilities	19,128	15,032
Long-term liabilities:
Lease liability - net of current portion	6,257	7,145
Total long-term liabilities	6,257	7,145
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 authorized Shares issued and outstanding: 34,595,623 at January 31, 2024 and 34,171,138 at April 30, 2023	34	34
Additional paid-in capital	516,920	507,133
Accumulated deficit	(425,077)	(343,082)
Accumulated other comprehensive loss	(3,294)	(3,060)
Total stockholders’ equity	88,583	161,025
Total liabilities and stockholders’ equity	$ 113,968	$ 183,202

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

CEO	Mr. Thomas Andrew Crockett M.B.A.
WEBSITE	kalvista.com
INDUSTRY	Biotechnology
EMPLOYEES	118

KalVista Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for KalVista Pharmaceuticals Inc? What does KALV stand for in stocks?

KALV is the stock ticker symbol of KalVista Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of KalVista Pharmaceuticals Inc (KALV)?

As of Mon Apr 29 2024, market cap of KalVista Pharmaceuticals Inc is 464.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KALV stock?

You can check KALV's fair value in chart for subscribers.

What is the fair value of KALV stock?

You can check KALV's fair value in chart for subscribers. The fair value of KalVista Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of KalVista Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KALV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is KalVista Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether KALV is over valued or under valued. Whether KalVista Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact KalVista Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALV.

What is KalVista Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, KALV's PE ratio (Price to Earnings) is -4.29 and Price to Sales (PS) ratio is 43.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALV PE ratio will change depending on the future growth rate expectations of investors.